Goelzer Investment Management’s Pacira BioSciences PCRX Stock Holding History

Goelzer Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31,495	Closed	-$1.84M	–	230
2022 Q2	$1.84M	Buy	31,495 +290	+0.9%	+$19K	0.18%	129
2022 Q1	$2.38M	Buy	31,205 +11,276	+57%	+$752K	0.21%	123
2021 Q4	$1.2M	Sell	19,929 -728	-4%	-$40.1K	0.1%	154
2021 Q3	$1.16M	Sell	20,657 -544	-3%	-$31.4K	0.1%	155
2021 Q2	$1.29M	Buy	21,201 +196	+0.9%	+$12.4K	0.11%	156
2021 Q1	$1.47M	Sell	21,005 -1,161	-5%	-$82.9K	0.13%	152
2020 Q4	$1.33M	Sell	22,166 -111	-0.5%	-$6.5K	0.12%	150
2020 Q3	$1.34M	Buy	+22,277	New	+$1.29M	0.12%	156

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Goelzer Investment Management's PCRX Position: Q3 2022 in Review

Goelzer Investment Management sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 31,495 shares — an estimated $1.84M sold.

Goelzer Investment Management first reported a position in PCRX in Q3 2020 and held it in 8 quarters. The position peaked at $2.38M in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Goelzer Investment Management reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
Goelzer Investment Management sold 31,495 Pacira BioSciences shares in Q3 2022, an estimated $1.84M.
Goelzer Investment Management first reported a position in Pacira BioSciences in Q3 2020 and held it in 8 quarters.
Goelzer Investment Management's Pacira BioSciences position peaked at $2.38M in Q1 2022.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Goelzer Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.